Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

Ashtrom Group Ltd. has issued bonds to refinance the company
Real Estate

Ashtrom Group Ltd. has issued bonds to refinance the company

Ashtrom Group Ltd. has raised funds to refinance the company for further development.

Learn more
Azrieli Group Ltd. has raised capital through a bond placement
Real Estate

Azrieli Group Ltd. has raised capital through a bond placement

Azrieli Group Ltd. has completed a fundraising to refinance and develop the company.

Learn more
REIT 1 Ltd. has raised capital through a bond placement
Real Estate

REIT 1 Ltd. has raised capital through a bond placement

REIT 1 Ltd. has completed a fundraising to refinance and develop the company.

Learn more